Abstract
The first example of mitochondrial delivery of the anticancer drug doxorubicin (Dox) is presented by lipid-functionalized DNA nanocages (LNCs). Dox localized in mitochondria induces significant cytotoxicity and cellular apoptosis in MCF-7 compared with Dox localized in lysosomes. These results suggest that LNC has the potential to be an outstanding tool in the treatment of specific organelle-related diseases such as cancers. Delivery of the anticancer drug doxorubicin to mitochondria by lipid-functionalized DNA nanocages (LNCs) is demonstrated for the first time. The results suggest outstanding potential for the use of LNCs as drug nanocarriers in treatments for organelle-specific diseases.
| Original language | English |
|---|---|
| Pages (from-to) | 770-781 |
| Number of pages | 12 |
| Journal | Small |
| Volume | 12 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 10 Feb 2016 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
User-Defined Keywords
- anticancer drugs
- delivery
- DNA nanocarriers
- lipophilic molecules
- mitochondria
Fingerprint
Dive into the research topics of 'Mitochondrial Delivery of Therapeutic Agents by Amphiphilic DNA Nanocarriers'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver